VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis-Reference-Cited by-同舟云学术

VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis

Published:2000-11 Issue:1-2 Volume:111 Page:186-194
ISSN:0165-5728
Container-title:Journal of Neuroimmunology
language:en
Short-container-title:Journal of Neuroimmunology

Author:

Muraro P.A,Leist T,Bielekova B,McFarland H.F

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,Immunology,Immunology and Allergy

Reference25 articles.

1. Heterogeneity of the circulating human CD4+ T cell population: further Evidence that the CD4+CD45RA−CD27− T cell subset contains specialized primed T cells;Baars;J. Immunol.,1995

2. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta;Calabresi;Neurology,1997

3. The adhesion molecule and cytokine profile of multiple sclerosis lesions;Cannella;Ann. Neurol.,1995

4. Microglial production of TNF-a is induced by activated T lymphocytes: involvement of VLA-4 and inhibition by interferon β-1b;Chabot;J. Clin. Invest.,1997

5. The CD27− subset of peripheral blood memory CD4+ lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo;de Jong;Eur. J. Immunol.,1992

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?;Current Neuropharmacology;2024-07

2. Selected Clostridia Strains from The Human Microbiota and their Metabolite, Butyrate, Improve Experimental Autoimmune Encephalomyelitis;Neurotherapeutics;2021-04

3. Efficacy of β-D-Mannuronic Acid [M2000] on the Pro-Apoptotic Process and Inflammatory-Related Molecules NFκB, IL-8 and Cd49d using Healthy Donor PBMC;Current Drug Discovery Technologies;2020-06-19

4. Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer?;Journal of the Neurological Sciences;2019-09

5. Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins in Multiple Sclerosis - Peginterferon Beta-1a, Daclizumab Beta, Natalizumab;Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases;2019-02-15